Pfizer believe that its inhaled insulin "bong" Exubera can reach $2 billion in sales, a forecast the company repeated to analysts in January.
“I think Pfizer is on drugs” if it believes it will get $2 billion a year from Exubera, said David Kliff, publisher of Diabetic Investor, a specialist investment data company. If Pfizer does reach its goal, “I’m going to run down Madison Avenue naked,” he says.
Much much more at BrandWeek
“I think Pfizer is on drugs” if it believes it will get $2 billion a year from Exubera, said David Kliff, publisher of Diabetic Investor, a specialist investment data company. If Pfizer does reach its goal, “I’m going to run down Madison Avenue naked,” he says.
Much much more at BrandWeek
No comments:
Post a Comment